Procter & Gamble (P&G) and Johnson & Johnson (J&J) both recently increased their long-standing dividends, but P&G's dividend appears more stable due to no planned corporate changes. J&J is preparing a mid-2027 spinoff of its DePuy Synthes unit, which could disrupt its dividend streak despite strong revenue growth. P&G's fiscal 2026 showed organic sales growth and over $15 billion returned to shareholders, supporting its dividend stability. Investors seeking reliable retirement income may prefer P&G for its consistent dividend strategy and absence of structural changes, while J&J's upcoming spinoff poses some uncertainty.
Johnson & Johnson is rated HOLD for the next 6-12 months due to balanced risks. Its drug portfolio growth offsets losses from Stelara, but the MedTech segment remains a weak growth driver. The company's valuation is above historical averages, reflect...
JPMorgan's JEPI ETF has seen its monthly payouts decrease throughout 2026 despite the S&P 500 rallying strongly. JEPI's strategy of selling option premiums on low-volatility stocks limits upside gains, making it underperform in a calm, rising market....
The Health Care Select Sector SPDR Fund (XLV) offers broad healthcare exposure but delivers a low dividend yield around 1.5% due to its cap-weighted structure favoring large, lower-yield stocks like Eli Lilly. Directly owning top XLV holdings AbbVie,...
Despite two major recessions in the past two decades, four healthcare companies—Johnson & Johnson, Abbott Laboratories, Medtronic, and Becton Dickinson—consistently raised their dividends each quarter. Their strong cash flows and inelastic demand for...
Coca-Cola, Johnson & Johnson, and Procter & Gamble have consistently increased their dividends through every U.S. recession since 1970, making them reliable income sources for retirees. These companies boast strong cash flows, solid balance sheets, a...
